clinical trial · NCT07499700
A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
Bio-Thera Solutions·phase3·recruiting·n = 192
Minimal Change Disease (MCD)Focal Segmental Glomerulosclerosis (FSGS)BAT4406FPlacebos
brief summary
This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of BAT4406F injection in patients with Minimal Change Disease/Focal Segmental Glomerulosclerosis
started
Oct 26, 2025
primary completion
Oct 26, 2030
completion
Nov 26, 2030
last updated
Apr 3, 2026
official title
A Phase II/III Clinical Study Evaluating the Efficacy and Safety of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol